Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology.
Flawless balance sheet with limited growth.
Share Price & News
How has Principia Biopharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2K1's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 2K1 exceeded the German Biotechs industry which returned -8.1% over the past year.
Return vs Market: 2K1 exceeded the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Principia Biopharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Principia Biopharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2K1 (€44.8) is trading below our estimate of fair value (€49.24)
Significantly Below Fair Value: 2K1 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 2K1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 2K1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2K1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2K1 is overvalued based on its PB Ratio (5.5x) compared to the DE Biotechs industry average (3.6x).
How is Principia Biopharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2K1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2K1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2K1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2K1's revenue (38.3% per year) is forecast to grow faster than the German market (4.1% per year).
High Growth Revenue: 2K1's revenue (38.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2K1's Return on Equity is forecast to be high in 3 years time
How has Principia Biopharma performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 2K1 is currently unprofitable.
Growing Profit Margin: 2K1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 2K1's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 2K1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2K1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: 2K1 has a negative Return on Equity (-14.98%), as it is currently unprofitable.
How is Principia Biopharma's financial position?
Financial Position Analysis
Short Term Liabilities: 2K1's short term assets ($319.7M) exceed its short term liabilities ($16.1M).
Long Term Liabilities: 2K1's short term assets ($319.7M) exceed its long term liabilities ($7.6M).
Debt to Equity History and Analysis
Debt Level: 2K1 is debt free.
Reducing Debt: 2K1 had no debt 5 years ago.
Inventory Level: 2K1 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 2K1's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2K1 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 2K1 has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of -55.9% each year.
What is Principia Biopharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2K1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 2K1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2K1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2K1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2K1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Matt Babler (54yo)
Mr. Martin Babler, also known as Matt, PhD serves as the Chief Executive Officer of Principia Biopharma Inc since April 2011 and also serves as its President from April 16, 2019. Mr. Babler served as the C ...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD2.32M) is about average for companies of similar size in the German market ($USD1.85M).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
|Chief Development Officer||1.58yrs||US$1.35m||0.11% $1.9m|
|Chief Medical Officer||1.42yrs||US$3.68m||0.0015% $26.9k|
|Chief Financial Officer||6yrs||US$653.30k||0.024% $438.2k|
|Chief Scientific Officer||no data||no data||0.094% $1.7m|
|VP of Corporate Communications||no data||no data||no data|
|Chief Business Officer||5.17yrs||no data||0.36% $6.5m|
|Senior Vice President of People||no data||no data||no data|
|Senior Vice President of Development Operations||no data||no data||no data|
|Senior VP of Commercial & Project Team Leader||no data||no data||no data|
Experienced Management: 2K1's management team is seasoned and experienced (5.2 years average tenure).
|Chairman of the Board||3yrs||US$306.29k||no data|
|Independent Director||9.17yrs||US$258.27k||no data|
|Board Observer||no data||no data||no data|
|Director||0.58yr||no data||no data|
|Independent Director||3.17yrs||US$256.05k||no data|
|Independent Director||0.83yr||no data||no data|
|Director||0.67yr||no data||no data|
Experienced Board: 2K1's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 238.2%.
Principia Biopharma Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Principia Biopharma Inc.
- Ticker: 2K1
- Exchange: DB
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.978b
- Listing Market Cap: US$1.793b
- Shares outstanding: 33.01m
- Website: https://www.principiabio.com
Number of Employees
- Principia Biopharma Inc.
- 220 East Grand Avenue
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PRNB||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Sep 2018|
|2K1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2018|
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 00:15|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.